Acta NaturaeActa NaturaeActa Naturae2075-8251Acta Naturae Ltd2767710.32607/actanaturae.27677ReviewsОбзорыReview ArticleTargeted radionuclide detection of malignant tumors using affibodyТаргетная радионуклидная детекция злокачественных опухолей с использованием аффибодиhttps://orcid.org/0000-0001-5281-775857190936256E-9732-20177961-5918BraginaOlga D.БрагинаОльга Дмитриевна
Russian Federation
rungis@mail.ruhttps://orcid.org/0009-0000-1661-7396NesynovAlexander A.НесыновАлександр Александрович
Russian Federation
nesynov.alex@mail.ruSitnikovaEkaterina Yu.СитниковаЕкатерина Юрьевна
Russian Federation
sitnikova_katerina00@mail.ruhttps://orcid.org/0000-0002-9468-198056324415300D-2358-20128497-1750PatalyakStanislav V.ПаталякСтанислав Викторович
Russian Federation
patalyak@gmail.comhttps://orcid.org/0000-0002-3952-06316603799895F-8191-20142562-1845DeyevSergey M.ДеевСергей Михайлович
Russian Federation
biomem@mail.ruTomsk Cancer Research InstituteФедеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук»National Research Tomsk Polytechnic UniversityФедеральное государственное автономное образовательное учреждение высшего образования «Национальный исследовательский Томский политехнический университет»Siberian State Medical UniversityФедеральное государственное бюджетное образовательное учреждение высшего образования «Сибирский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииShemyakin-Ovchinnikov Institute of Biorganic Chemistry of the Russian Academy of SciencesФедеральное государственное бюджетное научное учреждение науки Государственный научный центр Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук041220251744162204202506082025Copyright ©; 2025, Bragina O.D., Nesynov A.A., Sitnikova E.Y., Patalyak S.V., Deyev S.M.Copyright ©; 2025, Брагина О.Д., Несынов А.А., Ситникова Е.Ю., Паталяк С.В., Деев С.М.2025Bragina O.D., Nesynov A.A., Sitnikova E.Y., Patalyak S.V., Deyev S.M.Брагина О.Д., Несынов А.А., Ситникова Е.Ю., Паталяк С.В., Деев С.М.https://creativecommons.org/licenses/by/4.0https://actanaturae.ru/2075-8251/article/view/27677

This review examines the potential applications of affibody molecules in various fields of biotechnology and clinical medicine. Consideration is given to the high affinity and specificity of affibody molecules for selected molecular targets, as well as their potential for the in vivo visualization of various malignant tumors. Significant attention is paid to preclinical and clinical studies of affibody conjugates with various radioisotopes for targeted radionuclide tumor imaging, which is particularly relevant in addressing challenges encountered during the diagnosis and treatment of these patients. Clinical trials demonstrate that radiopharmaceuticals are well-tolerated and effective for the assessment of tumor process prevalence and the determination of HER2/neu status in breast cancer patients, supporting further research.

В представленном обзоре рассмотрены возможности использования молекул аффибоди в различных областях биотехнологии и клинической медицины. Показана высокая аффинность и специ­фичность молекул аффибоди к выбранным молекулярным мишеням, а также возможность визуализации различных злокачественных опухолей in vivo. Большее внимание уделено доклиническим и клиническим исследованиям конъюгатов аффибоди с различными радиоизотопами для проведения таргетной радионуклидной визуализации опухолей, что представляет особую актуальность в рамках проблем, возникающих на этапах диагностики и лечения данной категории пациентов. В клинических испытаниях показана хорошая переносимость радиофармацевтических препаратов и эффективность их использования для оценки распространенности опухолевого процесса и определения статуса HER2/neu у больных раком молочной железы, что обуславливает перспективность проведения дальнейших исследований.

Malignant tumorstheranosticstargeted radionuclide diagnosticsalternative scaffold proteinsaffibodiesзлокачественные образованиятераностикатаргетная радионуклидная диагностикаальтернативные каркасные белкиаффибодиМинистерство науки и высшего образования РФMinistry of Science and Higher Education of Russian Federation075-15-2024-536Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi: 10.3322/caac.21834Kaprin AD, Starinskii VV, Shakhzadova AO, eds. Zlokachestvennye novoobrazovaniia v Rossii v 2023 godu (zabolevaemost i smertnost) [Malignant neoplasms in Russia in 2023 (morbidity and mortality)]. P.A. Gertsen Moscow Oncology Research Institute; 2024.Злокачественные новообразования в России в 2023 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024.Cai A, Chen Y, Wang LS, Cusick JK, Shi Y. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer. Cancers (Basel). 2024;16(15):2635. doi: 10.3390/cancers16152635Cai A, Chen Y, Wang LS, et al. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer. Cancers (Basel). 2024;16(15):2635. doi: 10.3390/cancers16152635Cai M, Song XL, Li XA, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;68:100962. doi: 10.1016/j.drup.2023.100962Wang L, Wang X, Zhu X, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23(1):66. doi: 10.1186/s12943-024-01967-3Passaro A, Al Bakir M, Hamilton EG, et al. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024;187(7):1617-1635. doi: 10.1016/j.cell.2024.02.041Chae KJ, Hong H, Yoon SH, et al. Non-diagnostic Results of Percutaneous Transthoracic Needle Biopsy: A Meta-analysis. Sci Rep. 2019;9(1):12428. doi: 10.1038/s41598-019-48805-xLaurent F, Montaudon M, Latrabe V, Bégueret H. Percutaneous biopsy in lung cancer. Eur J Radiol. 2003;45(1):60-68. doi: 10.1016/s0720-048x(02)00286-3Kemeny MM, Busch-Devereaux E, Merriam LT, O’Hea BJ. Cancer surgery in the elderly. Hematol Oncol Clin North Am. 2000;14(1):169-192. doi: 10.1016/s0889-8588(05)70283-5Nicolò E, Serafini MS, Munoz-Arcos L, et al. Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications. J Liq Biopsy. 2023;2:100117. doi: 10.1016/j.jlb.2023.100117Hou Y, Nitta H, Li Z. HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept. Cancers (Basel). 2023;15(10):2664. doi: 10.3390/cancers15102664Hamilton E, Shastry M, Shiller SM, Ren R. Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev. 2021;100:102286. doi: 10.1016/j.ctrv.2021.102286Laprovitera N, Riefolo M, Ambrosini E, Klec C, Pichler M, Ferracin M. Cancer of Unknown Primary: Challenges and Progress in Clinical Management. Cancers (Basel). 2021;13(3):451. doi: 10.3390/cancers13030451Laprovitera N, Riefolo M, Ambrosini E, et al. Cancer of Unknown Primary: Challenges and Progress in Clinical Management. Cancers (Basel). 2021;13(3):451. doi: 10.3390/cancers13030451Harms PW, Frankel TL, Moutafi M, et al. Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists. Mod Pathol. 2023;36(7):100197. doi: 10.1016/j.modpat.2023.100197Lino-Silva LS, Gamboa-Domínguez A, Zúñiga-Tamayo D, López-Correa P. Interobserver variability in colorectal cancer and the 2016 ITBCC concensus. Mod Pathol. 2019;32(1):159-160. doi: 10.1038/s41379-018-0027-5Wu Q, Xu L. Challenges in HER2-low breast cancer identification, detection, and treatment. Transl Breast Cancer Res. 2024;5:3. doi: 10.21037/tbcr-23-48Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJM. The Future of Precision Oncology. Int J Mol Sci. 2023;24(16):12613. doi:10.3390/ijms241612613Rulten SL, Grose RP, Gatz SA, et al. The Future of Precision Oncology. Int J Mol Sci. 2023;24(16):12613. doi:10.3390/ijms241612613Langbein T, Weber WA, Eiber M. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. J Nucl Med. 2019;60(S2):13S-19S. doi: 10.2967/jnumed.118.220566Langbein T, Weber WA, Eiber M. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. J Nucl Med. 2019;60(2):13S-19S. doi: 10.2967/jnumed.118.220566Idée JM, Louguet S, Ballet S, Corot C. Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint. Quant Imaging Med Surg. 2013;3(6):292-297. doi: 10.3978/j.issn.2223-4292.2013.12.06Klain M, Nappi C, Zampella E, et al. Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(13):4437-4444. doi: 10.1007/s00259-021-05440-xBauckneht M, Ciccarese C, Laudicella R, et al. Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives. Cancer Treat Rev. 2024;124:102698. doi: 10.1016/j.ctrv.2024.102698Kasi PB, Mallela VR, Ambrozkiewicz F, Trailin A, Liška V, Hemminki K. Theranostics Nanomedicine Applications for Colorectal Cancer and Metastasis: Recent Advances. Int J Mol Sci. 2023;24(9):7922. doi: 10.3390/ijms24097922Song Y, Zou J, Castellanos EA, et al. Theranostics − a sure cure for cancer after 100 years? Theranostics. 2024;14(6):2464-2488. doi: 10.7150/thno.96675Burkett BJ, Bartlett DJ, McGarrah PW, et al. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements. Radiol Imaging Cancer. 2023;5(4):e220157. doi: 10.1148/rycan.220157Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19(8):534-550. doi: 10.1038/s41571-022-00652-yBodei L, Herrmann K, Schöder H, et al. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19(8):534-550. doi: 10.1038/s41571-022-00652-yWei Z, Li B, Wen X, et al. Engineered Antibodies as Cancer Radiotheranostics. Adv Sci (Weinh). 2024;11(30):e2402361. doi: 10.1002/advs.202402361Bragina OD, Chernov VI, Garbukov EYu, et al. Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use. Bull Sib Med. 2021;20(1):23-30. doi: 10.20538/1682-0363-2021-1-23-30Bragina OD, Chernov VI, Garbukov EYu, et al. Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use. Bulletin of Siberian Medicine. 2021;20(1):23-30. doi: 10.20538/1682-0363-2021-1-23-30Tolmachev V, Vorobyeva A. Radionuclides in Diagnostics and Therapy of Malignant Tumors: New Development. Cancers (Basel). 2022;14(2):297. doi: 10.3390/cancers14020297Bragina OD, Deyev SM, Chernov VI, Tolmachev VM. The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer. Acta Naturae. 2022;14(2):4-15. doi: 10.32607/actanaturae.11611Luo R, Liu H, Cheng Z. Protein scaffolds: antibody alternatives for cancer diagnosis and therapy. RSC Chem Biol. 2022;3(7):830-847. doi: 10.1039/d2cb00094fTolmachev V, Orlova A, Sörensen J. The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. Semin Cancer Biol. 2021;72:185-197. doi: 10.1016/j.semcancer.2020.10.005Shipunova VO, Deyev SM. Artificial Scaffold Polypeptides As an Efficient Tool for the Targeted Delivery of Nanostructures In Vitro and In Vivo. Acta Naturae. 2022;14(1):54-72. doi: 10.32607/actanaturae.11545Liu J, Cui D, Jiang Y, et al. Selection and characterization of a novel affibody peptide and its application in a two-site ELISA for the detection of cancer biomarker alpha-fetoprotein. Int J Biol Macromol. 2021;166:884-892. doi: 10.1016/j.ijbiomac.2020.10.245Zhu J, Kamara S, Cen D, et al. Correction: Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells. Cell Death Dis. 2020;11(6):494. doi: 10.1038/s41419-020-2692-9Liu S, Gao C, Tong Z, et al. A highly sensitive electrochemiluminescence method for abrin detection by a portable biosensor based on a screen-printed electrode with a phage display affibody as specific labeled probe. Anal Bioanal Chem. 2022;414(2):1095-1104. doi: 10.1007/s00216-021-03735-4Barozzi A, Lavoie RA, Day KN, Prodromou R, Menegatti S. Affibody-Binding Ligands. Int J Mol Sci. 2020;21(11):3769. doi: 10.3390/ijms21113769Barozzi A, Lavoie RA, Day KN, et al. Affibody-Binding Ligands. Int J Mol Sci. 2020;21(11):3769. doi: 10.3390/ijms21113769DiRusso CJ, Dashtiahangar M, Gilmore TD. Scaffold proteins as dynamic integrators of biological processes. J Biol Chem. 2022;298(12):102628. doi: 10.1016/j.jbc.2022.102628Ståhl S, Gräslund T, Eriksson Karlström A, Frejd FY, Nygren PÅ, Löfblom J. Affibody Molecules in Biotechnological and Medical Applications. Trends Biotechnol. 2017;35(8):691-712. doi: 10.1016/j.tibtech.2017.04.007Ståhl S, Gräslund T, Eriksson Karlström A, et al. Affibody Molecules in Biotechnological and Medical Applications. Trends Biotechnol. 2017;35(8):691-712. doi: 10.1016/j.tibtech.2017.04.007Hersh J, Yang YP, Roberts E, et al. Targeted Bioluminescent Imaging of Pancreatic Ductal Adenocarcinoma Using Nanocarrier-Complexed EGFR-Binding Affibody-Gaussia Luciferase Fusion Protein. Pharmaceutics. 2023;15(7):1976. doi: 10.3390/pharmaceutics15071976Du W, Jiang P, Li Q, et al. Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants. Microbiol Spectr. 2023;11(1):e0356222. doi: 10.1128/spectrum.03562-22Gabriele F, Palerma M, Ippoliti R, Angelucci F, Pitari G, Ardini M. Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy. Int J Mol Sci. 2023;24(10):8680. doi: 10.3390/ijms24108680Cai W, Lv W, Meng L, Duan Y, Zhang L. The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer. Int J Nanomedicine. 2023;18:339-351. doi: 10.2147/IJN.S387409Wu Y, Li H, Yan Y, et al. Affibody-Modified Gd@C-Dots with Efficient Renal Clearance for Enhanced MRI of EGFR Expression in Non-Small-Cell Lung Cancer. Int J Nanomedicine. 2020;15:4691-4703. doi: 10.2147/IJN.S244172Zhou H, Liu H, Zhang Y, et al. “PFH/AGM-CBA/HSV-TK/LIPOSOME-Affibody”: Novel Targeted Nano Ultrasound Contrast Agents for Ultrasound Imaging and Inhibited the Growth of ErbB2-Overexpressing Gastric Cancer Cells. Drug Des Devel Ther. 2022;16:1515-1530. doi: 10.2147/DDDT.S351623Zhou H, Liu H, Zhang Y, et al. «PFH/AGM-CBA/HSV-TK/LIPOSOME-Affibody»: Novel Targeted Nano Ultrasound Contrast Agents for Ultrasound Imaging and Inhibited the Growth of ErbB2-Overexpressing Gastric Cancer Cells. Drug Des Devel Ther. 2022;16:1515-1530. doi: 10.2147/DDDT.S351623Pinto Salgueiro G, Yilmaz O, Nogueira M, Torres T. Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa. BioDrugs. 2025;39(1):53-74. doi: 10.1007/s40259-024-00687-wKerschbaumer A, Smolen JS, Ferreira RJO, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2024;83(6):760-774. doi: 10.1136/ard-2024-225534Ahmadzadehfar H, Seifert R, Afshar-Oromieh A, Kratochwil C, Rahbar K. Prostate Cancer Theranostics With 177Lu-PSMA. Semin Nucl Med. 2024;54(4):581-590. doi: 10.1053/j.semnuclmed.2024.02.007Ahmadzadehfar H, Seifert R, Afshar-Oromieh A, et al. Prostate Cancer Theranostics With 177Lu-PSMA. Semin Nucl Med. 2024;54(4):581-590. Doi :10.1053/j.semnuclmed.2024.02.007Salih S, Alkatheeri A, Alomaim W, Elliyanti A. Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges. Molecules. 2022;27(16):5231. doi: 10.3390/molecules27165231Zhang L, Zhang H. Recent advances of affibody molecules in biomedical applications. Bioorg Med Chem. 2024;113:117923. doi: 10.1016/j.bmc.2024.117923Rouanne M, Radulescu C, Adam J, Allory Y. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. World J Urol. 2021;39(5):1345-1355. doi: 10.1007/s00345-020-03498-0Mucileanu A, Chira R, Mircea PA. PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies. Med Pharm Rep. 2021;94(4):402-410. doi: 10.15386/mpr-2116Lin KX, Istl AC, Quan D, Skaro A, Tang E, Zheng X. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunol Immunother. 2023;72(12):3875-3893. doi: 10.1007/s00262-023-03520-5Lin KX, Istl AC, Quan D, et al. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunol Immunother. 2023;72(12):3875-3893. doi: 10.1007/s00262-023-03520-5Liang Z, Hu X, Hu H, Wang P, Cai J. Novel small 99mTc-labeled affibody molecular probe for PD-L1 receptor imaging. Front Oncol. 2022;12:1017737. doi: 10.3389/fonc.2022.1017737Liang Z, Hu X, Hu H, et al. Novel small 99mTc-labeled affibody molecular probe for PD-L1 receptor imaging. Front Oncol. 2022;12:1017737. doi: 10.3389/fonc.2022.1017737Zhao B, Li H, Xia Y, et al. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. J Hematol Oncol. 2022;15(1):153. doi: 10.1186/s13045-022-01364-7Getu AA, Tigabu A, Zhou M, Lu J, Fodstad Ø, Tan M. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer. 2023;22(1):43. doi: 10.1186/s12943-023-01751-9Getu AA, Tigabu A, Zhou M, et al. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer. 2023;22(1):43. doi: 10.1186/s12943-023-01751-9Oroujeni M, Bezverkhniaia EA, Xu T, et al. Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3. Pharmaceutics. 2022;14(9):1780. doi: 10.3390/pharmaceutics14091780Oroujeni M, Bezverkhniaia EA, Xu T, et al. Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3. Pharmaceutics. 2022;14(9):1780. doi:10.3390/pharmaceutics14091780Oroujeni M, Bezverkhniaia EA, Xu T, et al. Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3. Nucl Med Biol. 2023;124-125:108384. doi: 10.1016/j.nucmedbio.2023.108384Cai H, Li Z, Shi Q, et al. Preclinical evaluation of 68Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2023;50(10):2952-2961. doi: 10.1007/s00259-023-06260-xPapadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med. 2018;62:75-88. doi: 10.1016/j.mam.2017.11.007Ivanova M, Porta FM, D’Ercole M, et al. Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch. 2024;484(1):3-14. doi: 10.1007/s00428-023-03656-wWolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867-3872. doi: 10.1200/JCO.22.02864Giugliano F, Carnevale Schianca A, Corti C, et al. Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution. Cancers (Basel). 2023;15(5):1385. doi: 10.3390/cancers15051385Schrijver WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, Moelans CB, van Diest PJ. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. J Natl Cancer Inst. 2018;110(6):568-580. doi: 10.1093/jnci/djx273Schrijver WAME, Suijkerbuijk KPM, van Gils CH, et al. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. J Natl Cancer Inst. 2018;110(6):568-580. doi: 10.1093/jnci/djx273Han J, Chen Y, Zhao Y, et al. Pre-Clinical Study of the [18F]AlF-Labeled HER2 Affibody for Non-Invasive HER2 Detection in Gastric Cancer. Front Med (Lausanne). 2022;9:803005. doi: 10.3389/fmed.2022.803005Stewart D, Cristea M. Antibody-drug conjugates for ovarian cancer: current clinical development. Curr Opin Obstet Gynecol. 2019;31(1):18-23. doi: 10.1097/GCO.0000000000000515Luo H, Xu X, Ye M, Sheng B, Zhu X. The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies. PLoS One. 2018;13(1):e0191972. doi: 10.1371/journal.pone.0191972Luo H, Xu X, Ye M, et al. The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies. PLoS One. 2018;13(1):e0191972. doi: 10.1371/journal.pone.0191972Murciano-Goroff YR, Suehnholz SP, Drilon A, Chakravarty D. Precision Oncology: 2023 in Review. Cancer Discov. 2023;13(12):2525-2531. doi: 10.1158/2159-8290.CD-23-1194Hu X, Hu H, Li D, Wang P, Cai J. Affibody-based molecular probe 99mTc-(HE)3ZHER2:V2 for non-invasive HER2 detection in ovarian and breast cancer xenografts. Open Med (Wars). 2024;19(1):20241027. doi: 10.1515/med-2024-1027Hu X, Hu H, Li D, et al. Affibody-based molecular probe 99mTc-(HE)3ZHER2:V2 for non-invasive HER2 detection in ovarian and breast cancer xenografts. Open Med (Wars). 2024;19(1):20241027. doi: 10.1515/med-2024-1027Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101-126. doi: 10.1038/s41573-022-00579-0Dowling GP, Keelan S, Toomey S, Daly GR, Hennessy BT, Hill ADK. Review of the status of neoadjuvant therapy in HER2-positive breast cancer. Front Oncol. 2023;13:1066007. doi: 10.3389/fonc.2023.1066007Dowling GP, Keelan S, Toomey S, et al. Review of the status of neoadjuvant therapy in HER2-positive breast cancer. Front Oncol. 2023;13:1066007. doi: 10.3389/fonc.2023.1066007Zimmerman BS, Esteva FJ. Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer. Cancers (Basel). 2024;16(4):800. doi: 10.3390/cancers16040800Baum RP, Prasad V, Müller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med. 2010;51(6):892-897. doi: 10.2967/jnumed.109.073239Sörensen J, Sandberg D, Sandström M, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med. 2014;55(5):730-735. doi: 10.2967/jnumed.113.131243Sörensen J, Velikyan I, Sandberg D, et al. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT. Theranostics. 2016;6(2):262-271. doi: 10.7150/thno.13502Miao H, Sun Y, Jin Y, Hu X, Song S, Zhang J. Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients. Front Oncol. 2022;12:894767. doi: 10.3389/fonc.2022.894767Miao H, Sun Y, Jin Y, et al. Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients. Front Oncol. 2022;12:894767. doi: 10.3389/fonc.2022.894767Alhuseinalkhudhur A, Lindman H, Liss P, et al. Human Epidermal Growth Factor Receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer. J Nucl Med. 2023;64(9):1364-1370. doi: 10.2967/jnumed.122.265364Alhuseinalkhudhur A, Lindman H, Liss P, et al. Human Epidermal Growth Factor Receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer. J Nucl Med. 2023;64(9):1364−1370. doi: 10.2967/jnumed.122.265364Altena R, Burén SA, Blomgren A, et al. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [68Ga]Ga-ABY-025: Results from a Pilot Study. J Nucl Med. 2024;65(5):700-707. doi: 10.2967/jnumed.123.266847Bragina O, Chernov V, Larkina M, et al. Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer. Theranostics. 2023;13(14):4858-4871. doi: 10.7150/thno.86770Bragina O, Chernov V, Larkina M, et al. Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer. Theranostics. 2023;13(14):4858−4871. doi: 10.7150/thno.86770